scholarly journals Metronomic vinorelbine is an excellent and safe treatment for advanced breast cancer: a retrospective, observational study

2021 ◽  
Vol 12 (17) ◽  
pp. 5355-5364
Author(s):  
Chien-Ting Liu ◽  
Meng-Che Hsieh ◽  
Yu-Li Su ◽  
Chaio-Ming Hung ◽  
Sung-Nan Pei ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Observational Study ◽  
Advanced Breast Cancer ◽  
Advanced Breast ◽  
Retrospective Observational Study ◽  
Safe Treatment ◽  
Metronomic Vinorelbine

scholarly journals Effectiveness and safety of eribulin in Japanese patients with HER2-negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting

2020 ◽  
Vol 38 (5) ◽  
pp. 1540-1549
Author(s):  
Kenichi Inoue ◽  
Masato Takahashi ◽  
Hirofumi Mukai ◽  
Takashi Yamanaka ◽  
Chiyomi Egawa ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Observational Study ◽  
Confidence Interval ◽  
Advanced Breast Cancer ◽  
Advanced Breast ◽  
Line Treatment ◽  
Second Line ◽  
Treatment Groups ◽  
Post Marketing ◽  
Grade 3

Summary Background Data on eribulin as the first- or second-line treatment in a clinical setting, especially the overall survival (OS) of patients, are scarce. Therefore, we assessed the effectiveness and safety of eribulin as the first-, second-, and third- or later-line treatments in patients with human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in Japan. Methods This multicenter, prospective, post-marketing, observational study enrolled patients from September 2014 to February 2016 in Japan and followed them for 2 years. Patients were categorized by eribulin use into the first-, second-, and third- or later-line treatment groups. Results Of 651 registered patients, 637 patients were included in the safety and effectiveness analysis. In all, first-, second-, and third or later-line treatment groups, median OS (95% confidence interval) were 15.6 (13.8–17.6), 22.8 (17.3–31.0), 16.3 (12.4–19.9), and 12.6 (11.2–15.1) months and time to treatment failure (TTF) (95% confidence interval) were 4.2 (3.7–4.4), 5.2 (3.7–5.9), 4.2 (3.7–5.1), and 3.8 (3.5–4.2) months, respectively. Prolonged TTF was associated with complications of diabetes and the development of peripheral neuropathy after eribulin treatment, according to multivariate Cox regression analysis. Grade ≥ 3 adverse drug reactions (ADRs) were reported in 61.7% of the patients. Neutropenia (49.5%) was the most common grade ≥ 3 ADR in all groups. Conclusions The effectiveness and safety results of eribulin as the first- or second-line treatment were favorable. Thus, these suggest eribulin may be a first-line treatment candidate for patients with HER2-negative advanced breast cancer in Japan.

Abstract P3-15-02: Treat ER+ight Canadian prospective observational study in HR+ advanced breast cancer: 2nd interim analysis

2018 ◽  
Author(s):  
S Dent ◽  
N Califaretti ◽  
C Doyle ◽  
C Ferrario ◽  
E Chouinard ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Observational Study ◽  
Advanced Breast Cancer ◽  
Interim Analysis ◽  
Prospective Observational Study ◽  
Advanced Breast

scholarly journals The Use of Expectancy and Empathy When Communicating With Patients With Advanced Breast Cancer; an Observational Study of Clinician–Patient Consultations

2019 ◽  
Vol 10 ◽  
Author(s):  
Liesbeth Mirjam van Vliet ◽  
Anneke L. Francke ◽  
Maartje C. Meijers ◽  
Janine Westendorp ◽  
Hinke Hoffstädt ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Observational Study ◽  
Advanced Breast Cancer ◽  
Advanced Breast

Real-life effectiveness of T-DM1 in heavily pretreated HER2-positive advanced breast cancer patients: An Italian observational study.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e12019-e12019 ◽  
Author(s):  
Alessandra Fabi ◽  
Katia Cannita ◽  
Gianluigi Ferretti ◽  
Mariangela Ciccarese ◽  
Grazia Arpino ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Observational Study ◽  
Advanced Breast Cancer ◽  
Cancer Patients ◽  
Real Life ◽  
Advanced Breast ◽  
Breast Cancer Patients ◽  
Her2 Positive ◽  
Life Effectiveness ◽  
Heavily Pretreated

scholarly journals Real-world everolimus experience in postmenopausal HR+ HER2- advanced breast cancer women: Treat ER+ight Canadian prospective observational study 2nd subgroup analysis

2017 ◽  
Vol 28 ◽  
pp. v92
Author(s):  
C. Doyle ◽  
N. Califaretti ◽  
S. Dent ◽  
E. Chouinard ◽  
S.R. Perri ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Observational Study ◽  
Advanced Breast Cancer ◽  
Real World ◽  
Subgroup Analysis ◽  
Prospective Observational Study ◽  
Advanced Breast

scholarly journals 69TiP MADELINE Asia: A mobile app-based prospective observational study of patient reported outcomes in advanced breast cancer in Asia

2020 ◽  
Vol 31 ◽  
pp. S1269
Author(s):  
A.Y.P. Tai ◽  
M. Singh ◽  
J. Binko ◽  
K. Lilly ◽  
S. Chang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Observational Study ◽  
Advanced Breast Cancer ◽  
Patient Reported Outcomes ◽  
Prospective Observational Study ◽  
Mobile App ◽  
Advanced Breast ◽  
Patient Reported

98P Final results from AVANTI, a multicentre German observational study of first-line bevacizumab (BEV) + chemotherapy (CT) in >2000 patients (pts) with advanced breast cancer (aBC)

2021 ◽  
Vol 32 ◽  
pp. S65
Author(s):  
V. Mueller ◽  
M. Ruhnke ◽  
O. Hoffmann ◽  
A. Grafe ◽  
O. Tomé ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Observational Study ◽  
Advanced Breast Cancer ◽  
Advanced Breast ◽  
First Line
Sign in / Sign up

Export Citation Format

Share Document